Haftungsausschluss: Diese Website bündelt öffentlich verfügbare Daten aus offiziellen Quellen wie FDA, ClinicalTrials.gov, PubMed und SEC EDGAR nur zur allgemeinen Information. Sie stellt keine medizinische Beratung, Diagnose, Behandlungsempfehlung oder Anlageberatung dar.

PubMed

Unravelling the Immunotoxicity of Polycaprolactone Nanoparticles-Effects of Polymer Molecular Weight, Hydrolysis, and Blends.

PMID: 33050694 ·

S, a, n, d, r, a, , J, e, s, u, s, ;, , N, a, t, a, l, i, a, , B, e, r, n, a, r, d, i, ;, , J, e, s, s, i, c, a, , d, a, , S, i, l, v, a, ;, , M, a, r, i, a, n, a, , C, o, l, a, ç, o, ;, , J, o, ã, o, , P, a, n, ã, o, , C, o, s, t, a, ;, , P, e, d, r, o, , F, o, n, t, e, ;, , O, l, g, a, , B, o, r, g, e, s

ZeitschriftChemical research in toxicology
Jahr
PMID33050694

Zusammenfassung

Poly-ε-caprolactone (PCL) is a biodegradable polyester that has FDA and CE approval as a medical device. Nonetheless, the lack of toxicity exhibited by the polymer cannot be extrapolated to its nanomaterial conformation. Despite PCL-based NPs being widely studied in the biomedical field for their advantages as controlled drug delivery systems, little data describe PCL NPs' toxicity, particularly immunotoxicity. This work assessed different PCL-based delivery systems intended for protein delivery

Offizielle Quelle

Auf PubMed ansehen →

Daten aus PubMed / NCBI. Den Volltext und die aktuellsten Informationen finden Sie stets im offiziellen Eintrag.

↑